| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
18-positive (Natural Killer T) Cells1
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, 4102 [T. J. S., G. J. P. F., I. H. F., G. R. L.], and Cancer Immunology Program, Peter MacCallum Cancer Institute, East Melbourne, Victoria, 8006 [M. J. S.], Australia
The role of natural killer T (NKT) cells in the immune response to tumor cells has been largely unexplored. As a model of adoptive tumor immunotherapy, cells from the draining lymph nodes of mice immunized with a tumor-specific or irrelevant antigen were transferred to naïve recipients with established tumor. Inhibition of early tumor growth (day 4) required the transfer of both CD8+ and J
18+ (NKT) cells from immunized animals without regard to immunogen. In contrast, CD8+ cells, but not J18+ cells, were necessary for the inhibition of late tumor growth (day 8). Thus, the developing tumor changes in sensitivity to NKT-mediated events and the role for NKT cells cannot be replaced by the presence of tumor-specific cells during early tumor growth. This suggests that recruitment/activation of J18+ NKT cells is an important consideration during the immune therapy of early stage tumors.
This article has been cited by other articles:
|
|
 |
|
  H. Wakao, R. Wakao, S. Sakata, K. Iwabuchi, A. Oda, and H. Fujita In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer FASEB J, July 1, 2008; 22(7): 2223 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Renukaradhya, M. A. Khan, M. Vieira, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma Blood, June 15, 2008; 111(12): 5637 - 5645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis J. Immunol., October 15, 2007; 179(8): 5126 - 5136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Molling, J. A.E. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bontkes, H. J.J. van der Vliet, B. M. E. von Blomberg, R. J. Scheper, and A. J.M. van den Eertwegh Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma J. Clin. Oncol., March 1, 2007; 25(7): 862 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terabe, J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky A nonclassical non-V{alpha}14J{alpha}18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance J. Exp. Med., December 19, 2005; 202(12): 1627 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Chang, K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of {alpha}-galactosyl-ceramide loaded mature dendritic cells in cancer patients J. Exp. Med., May 2, 2005; 201(9): 1503 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsumoto, G. R. Leggatt, J. Zhong, X. Liu, R. L. de Kluyver, T. Peters, G. J. P. Fernando, A. Liem, P. F. Lambert, and I. H. Frazer Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors J Natl Cancer Inst, November 3, 2004; 96(21): 1611 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gumperz CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J. Leukoc. Biol., August 1, 2004; 76(2): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
